Setmelanotide (branded as Imcivree) targets the MC4R pathway in the brain, targeting the root cause of hunger in individuals with genetic obesity. Individuals living with genetic disorders such as pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome (BBS) can re-establish the function in this impaired pathway. Setmelanotide delivers messages to the brain that the body is satisfied to help with weight loss and management.
